Discovery of small molecule candidate therapeutics against neuroimmune targets in Alzheimer’s disease

Our drug discovery efforts have taught us several important lessons: 1) Focus efforts on disease-relevant pathophysiology processes integrated with strategic compound design. 2) Fail fast and early. 3) Complex diseases such as AD require interventions that target complementary disease drivers and therapeutic intervention time windows. 4) Dosing is the pharmacological basis of successful therapeutic intervention: what, when, and how - the RIGHT drug(s) at the RIGHT time(s) for the RIGHT disease mechanism. 5) The cytokine/synaptic dysfunction axis is a viable pathophysiology process for therapeutic intervention where proinflammatory cytokine dysregulation is part of the disease progression mechanism.